This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dulaimi, E. Articles by Cairns, P. Search for Related Content PubMed PubMed Citation Articles by Dulaimi, E. Articles by Cairns, P.

Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients

Departments of ¹ Surgical Oncology and ² Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and ³ Chestnut Hill Academy, Philadelphia, Pennsylvania

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

 
Purpose: Breast cancer is the most common malignancy in American women and the second leading cause of death from cancer. The genetic and epigenetic alterations that initiate and drive cancer can be used as targets for detection of neoplasia in bodily fluids. Tumor cell-specific aberrant promoter hypermethylation can be detected in nipple aspirate and ductal lavage from breast cancer patients. In this study, we examine serum, a more readily accessible bodily fluid known to contain neoplastic DNA from individuals with cancer, for methylation-based detection of breast neoplasia.

Experimental Design: We examined the promoter methylation status of three normally unmethylated biologically significant cancer genes, RAS association domain family protein 1A (RASSF1A), adenomatous polyposis coli (APC), and death-associated protein kinase (DAP-kinase), by sensitive methylation-specific PCR in 34 breast tumor and paired preoperative serum DNA. The 34 patients comprised 7 ductal carcinoma in situ (CIS), 3 lobular CIS, 5 stage I and 15 stage II to IV invasive ductal carcinomas, and 4 invasive lobular carcinomas. Normal and benign tissue and serum control DNA were also examined to determine the specificity of hypermethylation.

Results: Hypermethylation of one or more genes was found in 32 of 34 (94%) breast tumor DNA. APC was hypermethylated in 15 of 34 (47%), RASSF1A in 22 of 34 (65%), and DAP-kinase in 17 of 34 (50%) tumors. Twenty-six (76%) of the corresponding serum DNA were positive for promoter hypermethylation, including ductal CIS, lobular CIS, stage I disease, and lobular carcinoma patients. No hypermethylation of APC, RASSF1A, or DAP-kinase was observed in serum DNA from normal healthy women and patients with inflammatory breast disease or nonneoplastic breast tissue specimens. A gene unmethylated in the tumor DNA was always found to be unmethylated in the matched serum DNA (100% specificity).

Conclusions: Tumor cell specific promoter hypermethylation of APC, RASSF1A, and DAP-kinase is present in ductal CIS, lobular CIS, and all grades and stages of invasive breast cancer. Hypermethylation can be detected by methylation-specific PCR analysis in serum DNA from patients with preinvasive and early-stage breast cancer amenable to cure. If confirmed in additional studies, hypermethylation-based screening of serum, a readily accessible bodily fluid, may enhance early detection of breast cancer.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

 
Detection of breast cancer at an early stage is the key to successful treatment and outcome. In tumors confined to the breast at diagnosis, stage is the most important prognostic factor. Precursor lesions include at least two histologically defined types. Ductal carcinoma in situ (CIS) is a preinvasive lesion detected more often because the availability of mammography. Patients with localized ductal CIS are candidates for breast conserving surgery. A second entity, lobular CIS, is believed to represent a marker of increased risk for the development of invasive cancer. Within the category of invasive breast cancer, stage I (<2 cm) tumors have a better disease-free survival rate than higher stage tumors. However, 30% of women diagnosed with localized breast cancer develop metastatic disease. In the roughly 15% of invasive breast tumors not detected by mammography, lobular carcinomas are overrepresented. Despite the availability of mammography and prevalence of self-examination, there is still additional benefit to be gained from additional screening methodologies (1 , 2) . Novel approaches to early detection of breast neoplasia therefore merit examination.

The genetic and epigenetic alterations that initiate and drive tumorigenesis are promising targets for early detection because they may precede clinically obvious cancer, can be detected at sensitive levels, may be specific to tumor cells, and can potentially provide information about the prognosis and treatment of the disease (3 , 4) . CpG islands located in promoter regions of genes are normally unmethylated. In cancer cells, aberrant hypermethylation of these promoter regions is associated with transcriptional silencing. Hypermethylation is therefore an alternative mechanism for inactivation of tumor suppressor genes (5 , 6) . Because gene hypermethylation has been found to be a common and early alteration in many tumor types (7, 8, 9) , including breast (10 , 11) , it has emerged as a promising target for detection strategies in clinical specimens (3 , 4) . Several tumor suppressor and other cancer genes have been found to be hypermethylated in breast cancer but to be unmethylated in normal cells, e.g., RAS association domain family protein 1A (RASSF1A), adenomatous polyposis coli (APC), and death-associated protein kinase (DAP-kinase) genes (9 , 10 , 12 , 13) .

Detection of tumor suppressor gene hypermethylation in nipple aspirate fluid has been reported by ourselves (14) and in ductal lavage by others (15) . Serum or plasma is a more readily accessible bodily fluid, and provision of a specimen does not require the presence of a specialist. DNA is known to be released into serum/plasma, which is enriched for tumor DNA in cancer patients (16) . Several recent studies have shown that it is possible to detect tumor-specific genetic or epigenetic alterations in serum DNA from head and neck, lung, and colon cancer patients (17, 18, 19) . Importantly, tumor cell-specific DNA alterations in serum were not limited to patients with metastatic cancer but were also present in serum from patients with early or organ-confined tumors (17, 18, 19) . Neoplastic DNA in the serum most likely arises from cells that have left the site of the primary lesion and have invaded the circulatory system but lack the capacity of metastasis to new organs or may be released from the primary tumor as free DNA from nonviable (apoptotic) neoplastic cells (3 , 4) .

To determine the feasibility of detection of hypermethylated tumor DNA, we examined the methylation status of the APC, RASSF1A, and DAP-kinase genes in paired tumor and serum DNA from 34 patients with breast neoplasia, including ductal CIS, lobular CIS, stage I ductal and invasive lobular carcinoma, as well as in normal and benign disease tissue and serum control DNA.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

 
Specimen Collection and DNA Extraction.
After approval from the Institutional Review Board, we obtained breast tumor specimens via the Fox Chase Cancer Center Tumor Bank Facility and matched preoperative serum or plasma via the Fox Chase Cancer Center Biospecimen Repository from 34 patients, ages 34 to 90 years, with histologically verified breast neoplasia. There were 7 ductal CIS, 3 lobular CIS, 20 invasive ductal, and 4 cases of invasive lobular cancer. Tumors were graded and staged according to American Joint Committee on Cancer guidelines (20) . Serum specimens from 20 normal, healthy age-matched women and 8 women with benign breast disease were also obtained via the Fox Chase Cancer Center Biospecimen Repository. DNA previously extracted from five specimens of fibrocystic breast disease and five specimens of histologically normal (nonneoplastic) breast tissue were available for analysis (14) . Tumor tissue was obtained immediately after surgical resection and subsequently microdissected with the assistance of a pathologist. DNA was extracted from tissue or from 1.5 mL of serum or plasma using a standard technique of digestion with proteinase K in the presence of SDS at 37°C overnight followed by phenol/chloroform extraction (21) . Tumor specimen DNA was spooled out after precipitation with 100% ethanol. Serum DNA was precipitated with one tenth volume of 10 mol/L ammonium acetate, 2 µL of glycogen (Roche Diagnostics Corporation, Indianapolis, IN), and 2.5 volumes of 100% ethanol, followed by incubation at –20°C and centrifugation at top speed (16,000 relative centrifugal force). Approximately 50 ng of DNA were obtained from 1 mL of serum. For paraffin-embedded tissue, 10 7-µm sections were cut with a microtome and put on glass slides. The area of lobular CIS or ductal CIS, indicated by the pathologist, was removed with a razor blade, or needle depending on size, using an inverted microscope. The dissected tissue was placed directly into a microcentrifuge tube, washed with xylene, and DNA isolated as above.

Methylation-Specific PCR (MSP).
Specimen DNA (0.05 to 1 µg) was modified with sodium bisulfite, converting all unmethylated, but not methylated, cytosine to uracil followed by amplification with primers specific for methylated versus unmethylated DNA. The genes used in the breast cancer detection panel were APC (8) , RASSF1A (22) , and DAP-kinase (23) . The primer sequences used have all been previously reported and can be found in the report referenced after each gene. The primers for RASSF1A include CpG site positions 7 to 9 on the forward primer and 13 to 15 on the reverse primer as described previously (22) . PCR amplification of template DNA was performed for 31 to 36 cycles at 95°C denaturing, 58°C to 66°C annealing and 72°C extension with a final extension step of 5 minutes. Cycle number and annealing temperature depended on the primer set to be use, each of which had been previously optimized for the PCR technology in our laboratory. For each set of DNA modification and PCR, a cell line or tumor with known hypermethylation as a positive control, normal lymphocyte, or normal tissue DNA as a negative control and water with no DNA template as a control for contamination were included. If no tumor or cell line with known hypermethylation of particular gene was available, normal human lymphocyte DNA in vitro methylated with SssI methylase according to the manufacturers instructions (New England Biolab, Beverly, MA) was used as a positive control. After PCR, samples were run on a 6% nondenaturing acrylamide gel with a 20-bp ladder and analyzed.

Statistical Analysis.
The sensitivity of MSP-based detection of hypermethylation in serum was calculated as number of positive tests divided by number of cancer cases. The specificity was calculated as number of negative tests divided by number of cases without cancer and in a second, distinct approach as number of negative tests divided by number of cases without hypermethylation in serum. The association of tumor stage with positive detection in serum was compared using Fisher’s exact test. Results were considered statistically significant if the two-sided P was 0.05.

	RESULTS AND DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

 
We examined the methylation status of the normally unmethylated APC and RASSF1A tumor suppressor genes and the candidate metastasis inhibitor gene DAP-kinase, previously reported to be frequently hypermethylated in breast cancer (8, 9, 10 , 12, 13, 14) , in 34 breast tumor and matched serum or plasma DNA. The tumor set we studied included preinvasive and early-stage lesions (three lobular CIS, seven ductal CIS, and five stage I invasive ductal carcinomas) that have a better chance of cure with existing treatment options (2) . To detect promoter hypermethylation, we used the sensitive MSP assay, which can detect 0.1% cancer cell DNA from a heterogeneous cell population (24) . We found APC to be hypermethylated in 15 of 34 (47%), RASSF1A in 22 of 34 (65%), and DAP-kinase in 17 of 34 (50%) tumor DNA. Because no one gene was known to be hypermethylated in more than a proportion of breast tumors, it was necessary to use a panel of genes to provide a target for detection in the paired sera. Overall, 32 of 34 tumor DNA showed hypermethylation of at least one of the three genes from the panel, which provided a diagnostic coverage (whether a hypermethylated gene was available as a target in each case) of 94%. Hypermethylation was found in ductal CIS, lobular CIS, and invasive ductal and lobular tumors of all pathological grades and stages, which indicated that hypermethylation can be a relatively early event in breast tumorigenesis. Frequent hypermethylation of RASSF1A in ductal CIS has been reported previously (10) . In regard to whether lobular CIS is a high-risk marker or a precursor lesion, it will be interesting to additionally examine tumor suppressor gene hypermethylation in lobular CIS. Hypermethylation was found in patients of all ages (Table 1) . Three of 3 lobular CIS, 5 of 7 ductal CIS, 3 of 5 stage I, and 15 of 19 stage II to IV, and in total 26 of 34 (76%), patient serum DNA were positive for hypermethylation of a gene known to be methylated in the corresponding tumor DNA (Table 1 and Fig. 1 ). Positive detection of hypermethylation in serum was not associated with tumor stage (11 of 15 ductal CIS, lobular CIS, and stage I invasive ductal carcinoma versus 15 of 19 stage II to IV invasive ductal carcinoma and invasive lobular carcinoma; P = 1.0 Fisher’s exact test). In four cases (patients 2, 10, 13, and 29), where more than one gene was hypermethylated in the tumor DNA, not all of the methylated genes were detected in the paired serum DNA. This is likely attributable to differences in PCR amplification efficiencies between primer sets but will require further study.

View larger version (82K): [in this window] [in a new window]   Fig. 1. MSP of APC, RASSF1A, and DAP-kinase (DAP-K) genes in breast tumor and serum DNA. In the APC gel panel viewed from left to right, patients 15 and 18 tumor DNA is hypermethylated (M) and positively detected in the corresponding serum DNA (M), whereas patient 14’s tumor and serum DNA show no hypermethylation. In the top RASSF1A gel panel, patient 4’s ductal CIS (DCIS) and patient 2’s lobular CIS (LCIS) both show hypermethylation, which was detected in the corresponding sera. Patient 5’s tumor and serum DNA show no hypermethylation. In the bottom RASSF1A panel, patients 13 and 22 tumor DNA is hypermethylated (M) and positively detected in the corresponding serum DNA (M), whereas patient 14’s tumor and serum DNA show no hypermethylation. In the DAP-K panel, patient 19’s tumor shows hypermethylation, which was not detected in the corresponding serum DNA. Patient 24’s tumor and serum are unmethylated. Patient 14’s tumor DNA shows methylation, which was positively detected in the corresponding serum DNA. The PCR product in the unmethylated lane (U) from all tumor DNA arises from normal cell contamination of the tumor specimen or from an unmethylated allele. In vitro methylated DNA (APC and DAP-K) or tumor cell line MDA231 (RASSF1A) as a positive control, normal lymphocyte DNA as a negative control, a water control for contamination in the PCR reaction (right), and a 20-bp molecular ruler as a molecular weight marker (far left) are also shown.

There are several potential approaches to improving the level of sensitivity observed in our study. Most immediately, diagnostic coverage can likely be increased to 100% by addition of other genes hypermethylated in breast cancer to the panel. The need for a larger panel of genes reflects the genetic and epigenetic heterogeneity of breast cancer. Significantly larger panels of genes will remain manageable given emerging array technology. We believe that the sensitivity level of hypermethylation-based detection can also be improved upon by the study of optimal serum collection techniques, enrichment of neoplastic cells or DNA from the serum by antibody or oligo-based magnetic bead technology, and improvements in PCR technology.

We examined the tumor cell specificity of the three genes in our study with several different controls. In all cases, a gene unmethylated in the tumor DNA was found to be unmethylated in the matched serum DNA (Table 1) . This approach has been validated in previous MSP-based detection studies (17 , 18 , 26) . For example, tumor 14 in Fig. 1 did not have APC hypermethylation, and the matched serum DNA was also negative. Moreover, we did not observe APC, RASSF1A, or DAP-kinase hypermethylation in serum DNA from 20 normal, healthy age-matched controls and 8 patients with the benign breast disease (Fig. 2 and Table 2 ). We had previously examined six cases of fibrocystic disease and histologically normal breast tissue containing nonneoplastic cells from six breast cancer patients and observed no RASSF1A or DAP-Kinase hypermethylation in these nonneoplastic cells (14) . We also found these 12 nonneoplastic DNA to have unmethylated alleles of APC. Methylation of APC has been reported to be absent in previous studies of normal breast cells (13) . These findings indicate that aberrant promoter hypermethylation of tumor suppressor genes in serum can be highly specific for cancer. A recent study reported DAP-kinase hypermethylation in normal human lymphocytes by quantitative MSP analysis (27) . However, at our routine cycle numbers for conventional MSP, we did not observe DAP-kinase methylation in normal tissue or serum DNA. Future studies could use sufficient controls to address larger issues beyond our pilot study.

View larger version (72K): [in this window] [in a new window]   Fig. 2. MSP of APC, RASSF1A, and DAP-kinase (DAP-K) genes in normal and inflammatory disease control DNA. The absence of a PCR product in the methylated lane (M) of APC in normal breast tissue (NBT) DNA 1 to 6, of RASSF1A in benign disease tissue (BDT) DNA 1 to 6, of DAP-K in normal serum (NS) DNA 1 to 6, and of APC in serum DNA from patients with benign disease (BDS) 2 to 7 indicates that these specimen DNA have unmethylated alleles only (U). A primary tumor DNA with methylated alleles of APC, tumor cell line MDA231 (RASSF1A) and in vitro methylated DNA (DAP-K) as a positive control, normal lymphocyte DNA as a negative control, a water control for contamination in the PCR reaction (right), and a 20-bp molecular ruler as a molecular weight marker (far left) is also shown.

In this study, we have demonstrated sensitive and specific detection of hypermethylation in serum from breast cancer patients. The sensitivity observed in preinvasive or stage I lesions was 73% only slightly lower than the 79% in stage II to IV cancer. All three cases of lobular CIS examined demonstrated hypermethylation in the paired serum. One lobular CIS patient had a bilateral mastectomy and the other two patients had a lumpectomy. All three lobular CIS patients were free of disease 6 to 22 months after surgery. Our study also provides the first demonstration of methylation-based detection of ductal CIS and stage I ductal carcinoma in serum. Interestingly, we detected hypermethylation in the serum DNA from all four invasive lobular carcinoma patients. It is known that invasive lobular carcinoma is more often missed by mammography. Additional studies of the use of hypermethylation-based screening of serum should address improvements in sensitivity, the validation of specificity in larger numbers and examination of high-risk populations. If our results are confirmed in such studies, promoter hypermethylation may have useful clinical application in the detection of breast neoplasia.

	FOOTNOTES

 
Grant support: Avon/NIH supplement to Specialized Programs of Research Excellence through the National Cancer Institute Grant P50 CA083638 and the Howard Hughes Medical Institution Partnership For Cancer Research Grant 333260-1.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Paul Cairns, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: (215) 728-5635; Fax: (215) 728-2487; E-mail: Paul.Cairns{at}fccc.edu

Received 3/26/04; revised 5/19/04; accepted 5/24/04.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

 

1. Couch FJ, Weber BL Breast cancer Scriver CR Beaudet AL Sly WSet al eds. . The metabolic and molecular basis of human disease 2001p. 999-1031. McGraw-Hill New York
2. Leitch AM Breast cancer screening: success amid conflict. Surg Oncol Clin N Am 1999;8:657-72.[Medline]
3. Sidransky D Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.[CrossRef][Medline]
4. Laird PW The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.[CrossRef][Medline]
5. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa J-PJ Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.[Medline]
6. Jones PA, Laird PW Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.[CrossRef][Medline]
7. Belinsky SA, Nikula KJ, WAP, et al Aberrant methylation of p16^INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.[Abstract/Free Full Text]
8. Esteller M, Sparks A, Toyota M, et al Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.[Abstract/Free Full Text]
9. Esteller M, Corn PG, Baylin SB, Herman JG A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.[Abstract/Free Full Text]
10. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-12.[Abstract/Free Full Text]
11. Holst CR, Nuovo GJ, Esteller M, et al Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003;63:1596-601.[Abstract/Free Full Text]
12. Dammann R, Yang G, Pfeifer GP Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.[Abstract/Free Full Text]
13. Jin Z, Tamura G, Tsuchiya T, et al Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001;85:69-73.[CrossRef][Medline]
14. Krassenstein R, Sauter E, Dulaimi E, et al Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28-32.[Abstract/Free Full Text]
15. Evron E, Dooley WC, Umbricht CB, et al Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357:1335-6.[CrossRef][Medline]
16. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.[Abstract/Free Full Text]
17. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.[Abstract/Free Full Text]
18. Sanchez-Cespedes M, Esteller M, Wu L, et al Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.[Abstract/Free Full Text]
19. Hibi K, Robinson CR, Booker S, et al Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-7.[Abstract/Free Full Text]
20. Greene FL, Page DL, Fleming ID, et al . AJCC cancer staging manual 6th ed. 2002 American Joint Committee on Cancer New York
21. Sambrook J, Russell DW . Molecular cloning. A laboratory manual 2001 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
22. Dammann R, Li C, Yoon J-H, Chin PL, Bates S, Pfeifer GP Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9.[CrossRef][Medline]
23. Katzenellenbogen RA, Baylin SB, Herman JG Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-53.[Abstract/Free Full Text]
24. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.[Abstract/Free Full Text]
25. Silva JM, Dominguez G, Villanueva MJ, et al Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer 1999;80:1262-4.[CrossRef][Medline]
26. Cairns P, Esteller M, Herman JG, et al Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727-30.[Abstract/Free Full Text]
27. Reddy AN, Jiang WW, Kim M, et al Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res 2003;63:7694-8.[Abstract/Free Full Text]
28. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-8.[CrossRef][Medline]
29. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 2002;62:6634-8.[Abstract/Free Full Text]
30. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-5.[Abstract/Free Full Text]
31. Muller HM, Widschwendter A, Fiegl H, et al DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-5.[Abstract/Free Full Text]
32. Huang TH, Perry MR, Laux DE Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999;8:459-70.[Abstract/Free Full Text]
33. Wei SH, Chen CM, Strathdee G, et al Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002;8:2246-52.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. Kagan, S. Srivastava, P. E. Barker, S. A. Belinsky, and P. Cairns Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools Cancer Res., May 15, 2007; 67(10): 4545 - 4549. [Abstract] [Full Text] [PDF]

				R. Tetzner, D. Dietrich, and J. Distler Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA Nucleic Acids Res., January 12, 2007; 35(1): e4 - e4. [Abstract] [Full Text] [PDF]

				N. Umetani, A. E. Giuliano, S. H. Hiramatsu, F. Amersi, T. Nakagawa, S. Martino, and D. S.B. Hoon Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum J. Clin. Oncol., September 10, 2006; 24(26): 4270 - 4276. [Abstract] [Full Text] [PDF]

				E. PAPADOPOULOU, E. DAVILAS, V. SOTIRIOU, E. GEORGAKOPOULOS, S. GEORGAKOPOULOU, A. KOLIOPANOS, F. AGGELAKIS, K. DARDOUFAS, N. J AGNANTI, I. KARYDAS, et al. Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer. Ann. N.Y. Acad. Sci., September 1, 2006; 1075: 235 - 243. [Abstract] [Full Text] [PDF]

				O. E BRYZGUNOVA, T. E SKVORTSOVA, E. V KOLESNIKOVA, A. V STARIKOV, E. Y. RYKOVA, V. V VLASSOV, and P. P LAKTIONOV Isolation and Comparative Study of Cell-Free Nucleic Acids from Human Urine. Ann. N.Y. Acad. Sci., September 1, 2006; 1075: 334 - 340. [Abstract] [Full Text] [PDF]

				T. Mori, S. R. Martinez, S. J. O'Day, D. L. Morton, N. Umetani, M. Kitago, A. Tanemura, S. L. Nguyen, A. N. Tran, H.-J. Wang, et al. Estrogen Receptor-{alpha} Methylation Predicts Melanoma Progression. Cancer Res., July 1, 2006; 66(13): 6692 - 6698. [Abstract] [Full Text] [PDF]

				P. Cairns Serum-Based Detection of Gene Hypermethylation in Cancers of the Breast and Ovary Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 202 - 204. [Full Text] [PDF]

				T. Mori, S. J. O'Day, N. Umetani, S. R. Martinez, M. Kitago, K. Koyanagi, C. Kuo, T.-L. Takeshima, R. Milford, H.-J. Wang, et al. Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy J. Clin. Oncol., December 20, 2005; 23(36): 9351 - 9358. [Abstract] [Full Text] [PDF]

				T. V. Karpinets and B. D. Foy Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations Carcinogenesis, August 1, 2005; 26(8): 1323 - 1334. [Abstract] [Full Text] [PDF]

				K. Miyamoto and T. Ushijima Diagnostic and Therapeutic Applications of Epigenetics Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 293 - 301. [Abstract] [Full Text] [PDF]

				H. Fiegl, S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel, and M. Widschwendter Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer Patients Cancer Res., February 15, 2005; 65(4): 1141 - 1145. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dulaimi, E. Articles by Cairns, P. Search for Related Content PubMed PubMed Citation Articles by Dulaimi, E. Articles by Cairns, P.